Olaregen unaudited 3 month results
NOTE 7 - SUBSEQUENT EVENTS
Generex Biotechology Corporation. (“Generex”) Purchase of 51% of the Company’s outstanding shares
On January 7, 2019, the Company sold 3,282,632 shares of common stock. The price payable to the Company for the Purchase Shares will be an aggregate sum of $12,000,000 (the “Purchase Price”). The Company received an initial deposit of $400,000 on November 27, 2018 for the purchase of 106,666 shares of the Company’s Common Stock and received deposits totaling $1,000,000 as of March 11, 2019. The promissory note receivable of $10,600,000 from Generex Biotechnology Corporation as of March 11, 2019. The rate of interest is 7%. As of March 11, 2019, Generex has paid $1,000,000 against $1,600,000 due in January 2019. Generex had a 30 days grace period to make the $600,000 payment and has not done so as of March 11, 2019.
https://www.sec.gov/Archives/edgar/data/10597...ex99_2.htm
NOTE 7 - SUBSEQUENT EVENTS
Generex Biotechology Corporation. (“Generex”) Purchase of 51% of the Company’s outstanding shares
On January 7, 2019, the Company sold 3,282,632 shares of common stock. The price payable to the Company for the Purchase Shares will be an aggregate sum of $12,000,000 (the “Purchase Price”). The Company received an initial deposit of $400,000 on November 27, 2018 for the purchase of 106,666 shares of the Company’s Common Stock and received deposits totaling $1,000,000 as of March 11, 2019. The promissory note receivable of $10,600,000 from Generex Biotechnology Corporation as of March 11, 2019. The rate of interest is 7%. As of March 11, 2019, Generex has paid $1,000,000 against $1,600,000 due in January 2019. Generex had a 30 days grace period to make the $600,000 payment and has not done so as of March 11, 2019.
https://www.sec.gov/Archives/edgar/data/10597...ex99_2.htm
